title: Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
abstract: Neutralizing antibodies have a role in controlling hepatitis C virus (HCV) infection. A successful vaccine will need to elicit potently neutralizing antibodies that are capable of preventing the infection of genetically diverse viral isolates. However, the specificity of the neutralizing antibody response in natural HCV infection still is poorly understood. To address this, we examined the reactivity of polyclonal antibodies isolated from chronic HCV infection to the diverse patient-isolated HCV envelope glycoproteins E1 and E2 (E1E2), and we also examined the potential to neutralize the entry of pseudoparticles bearing these diverse E1E2 proteins. The genetic type of the infection was found to determine the pattern of the antibody recognition of these E1E2 proteins, with the greatest reactivity to homologous E1E2 proteins. This relationship was strongest when the component of the antibody response directed only to linear epitopes was analyzed. In contrast, the neutralization serotype did not correlate with genotype. Instead, serum-derived antibodies displayed a range of neutralization breadth and potency, while different E1E2 glycoproteins displayed different sensitivities to neutralization, such that these could be divided broadly into neutralization-sensitive and -resistant phenotypes. An important additional observation was that entry mediated by some E1E2 proteins was enhanced in the presence of some of the polyclonal antibody fractions isolated during chronic infection. These data highlight the need to use diverse E1E2 isolates, which represent extremes of neutralization sensitivity, when screening antibodies for therapeutic potential and for testing antibodies generated following immunization as part of vaccine development.
authors.affiliation: School of Molecular Medical Sciences, The University of Nottingham, A Floor West Block, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Tarr
authors.forename: Richard A
authors.initials: RA
authors.lastname: Urbanowicz
authors.forename: Mohamed R
authors.initials: MR
authors.lastname: Hamed
authors.forename: Anna
authors.initials: A
authors.lastname: Albecka
authors.forename: C Patrick
authors.initials: CP
authors.lastname: McClure
authors.forename: Richard J P
authors.initials: RJ
authors.lastname: Brown
authors.forename: William L
authors.initials: WL
authors.lastname: Irving
authors.forename: Jean
authors.initials: J
authors.lastname: Dubuisson
authors.forename: Jonathan K
authors.initials: JK
authors.lastname: Ball
mesh_terms: D019138:Antibodies, Blocking; D057134:Antibodies, Neutralizing / Q000097:blood*; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood*; D018936:Hepatitis C Antigens / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000276:immunology* / Q000821:virology*; D006801:Humans; D009500:Neutralization Tests; D012367:RNA, Viral / Q000235:genetics; D044967:Serum / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D053586:Virus Internalization
chemical_list: D019138:Antibodies, Blocking; D057134:Antibodies, Neutralizing; D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens; D012367:RNA, Viral; D014759:Viral Envelope Proteins